Hear from our team on recent breakthroughs, scientific and clinical advancements, company culture, and our ongoing work to develop new medicines at Kymera.
KT-621 is the first oral STAT6 targeted medicine to advance into the clinic, and we believe KT-621 can provide the convenience of a once daily oral pill with the potential to deliver biologics-like activity for patients suffering from highly prevalent allergic and atopic diseases around the world. Hear from our CEO, Nello Mainolfi, as he discusses the origin and opportunity of this milestone moment and what it means for patients.
Stay ahead with the latest news from Kymera. Our Press Releases provide insights into our recent achievements and future endeavors.